ReviewInstability, stabilization, and formulation of liquid protein pharmaceuticals
Introduction
The advent of recombinant DNA technology has led to a worldwide zeal to develop protein pharmaceuticals in the past two decades. These protein pharmaceuticals or pharmaceutical candidates include functional regulators and supplements, enzyme activators and inhibitors, poly- and monoclonal antibodies, and various vaccines. In comparison with small chemical drugs, protein pharmaceuticals have high specificity and activity at relatively low concentrations. These features have made protein pharmaceuticals indispensable in combating human diseases.
Due to advances in analytical separation technology, recombinant proteins can now be purified to an unprecedented level (Bond et al., 1998). Highly purified protein pharmaceuticals significantly reduce the known and unknown potential side or even toxic effects. However, one of the most challenging tasks remains in the development of protein pharmaceuticals: dealing with physical and chemical instabilities of proteins. Protein instability is one of the two major reasons why protein pharmaceuticals are administered traditionally through injection rather than taken orally like most small chemical drugs (Wang, 1996). Protein pharmaceuticals usually have to be stored under cold conditions or even freeze-dried to a solid form to achieve an acceptable shelf life.
In search for ways of stabilizing proteins, scientists turned their attention to nature for an answer. It is well known that certain natural organisms can grow well at extreme temperatures. Hyperthermophilic organisms (hyperthermophiles) such as anaerobic, methanogenic, or sulfate-reducing archaebacteria grow at temperatures near or above 100°C (Huber et al., 1989, Adams, 1993, Adams, 1994). Proteins in these organisms function normally at high temperatures. For example, enolase and α-glucosidase in hyperthermophilic Pyrococcus furiousus have optimum activity, at >90 and >105°C, respectively (Costantino et al., 1990, Peak et al., 1994). The most thermostable proteins found so far have half-lives in excess of 10 min at 130°C (Daniel et al., 1996). The mechanisms responsible for the high molecular stability of thermophilic proteins include increased hydrophobic interactions, greater molecular packing, more H-bonds, more salt-bridging, loss of surface loops, more helix-forming amino acids, restricted N-terminus mobility, etc. (Vieille and Zeikus, 1996, Cowan, 1997, Vogt and Argos, 1997). Extrinsic factors (not primary structure-related) have also contributed to protein stabilization. One of these is the high cellular content of sugars, salts, or other organic solutes/osmolytes, such as α-glutamate, di-myo-inositol-phosphate and its isomer, β-mannosylglycerate, and di-glycerol-phosphate (Huber et al., 1989, Rupley and Careri, 1991, Martins and Santos, 1995, Martins et al., 1997, Ramakrishnan et al., 1997).
The identification of intrinsic and extrinsic factors that contribute to the stabilization of thermophilic proteins has provided valuable information for stabilizing protein pharmaceuticals and for designing more stable mutant proteins. Yet the structural differences among different proteins are so significant that generalization of universal stabilization strategies has not been successful. Very often, proteins have to be evaluated individually and stabilized on a trial-and-error basis.
To understand and maximize the stability of protein pharmaceuticals or any other usable proteins such as various catalytic enzymes, many studies have been conducted in the past few decades. These studies have been reviewed with emphasis on general protein stability (Jaenicke, 1991, Kristjánsson and Kinsella, 1991), mechanisms of chemical and physical instabilities of proteins (Manning et al., 1989), mechanisms and prevention of major protein degradation pathways (Cleland et al., 1993), and various means of stabilizing proteins in aqueous or solid state and under various processing conditions such as freeze-thawing or drying (Gianfreda and Scarfi, 1991, Arakawa et al., 1993, Timasheff, 1993, Manning et al., 1995, Wong and Parascrampuria, 1997). This article reviews these investigations and achievements in recent years and discusses the basic behavior of proteins, their instabilities, and stabilization in aqueous state in relation to the development of liquid protein pharmaceuticals.
Section snippets
Basic protein behavior and properties
Protein pharmaceuticals, unlike small drug molecules, have high molecular weight (>5 kD). Their large size, compositional variety, and amphipathic characteristics constitute specific behavior such as folding, conformational stability, and unfolding/denaturation. Understanding proteins’ basic behavior may help toward their stabilization.
Protein instability and its influencing factors and analytical monitoring
One of the most troubling and challenging tasks in the development of liquid protein pharmaceuticals is to deal with their physical and chemical instabilities. The most common physical instability is protein aggregation, which can be induced and/or affected by a variety of factors and chemical transformations. Careful examination of these stability-influencing factors may help to prevent or mitigate certain stability problems. In addition, selection of proper and adequate analytical methods for
Stabilization and formulation of liquid protein pharmaceuticals
Proteins in extremophilic organisms can tolerate one or more of the following stresses: low or high temperatures, high hydrostatic pressure, high salinity, and extreme pHs, even though their building blocks are exclusively the canonical 20 natural amino acids. Therefore, significant room exists to stabilize any unstable protein pharmaceuticals. The central issue in protein stabilization is preservation of the functional state of proteins under various stressful conditions.
Conclusions
Native proteins are properly folded, which involves many forces, including hydrophobic interactions, electrostatic interactions (charge repulsion and ion pairing), hydrogen bonding, intrinsic propensities, and van der Waals forces. Among these forces, hydrophobic interactions seem to be the dominant. Proteins are generally not very stable, as stabilization energy of the native state is mostly between 5 and 20 kcal/mol, which is equivalent to that of a few hydrogen bonds. Most mesophilic
Acknowledgements
This manuscript would not be possible without the support of Drs Robert Kuhn and Rajiv Nayar. I am also indebted to Drs Rajiv Nayar and Mike Zachariou for the helpful discussions about the manuscript, the Editorial Services Department for careful editing, and especially, the two referees for their critical and valuable comments.
References (315)
- et al.
Monitoring of protein conformation by high-performance size-exclusion liquid chromatography and scanning diode array second-derivative UV absorption spectroscopy
J. Chromatogr.
(1991) Biochemical diversity among sulfur-dependent, hyperthermophilic microorganisms
FEMS Microbiol. Rev.
(1994)- et al.
Counteracting effects of thiocyanate and sucrose on chymotrypsinogen secondary structure and aggregation during freezing, drying and rehydration
Biophys. J.
(1996) - et al.
Factors affecting short-term and long term stabilities of proteins
Adv. Drug Deliv. Rev.
(1993) - et al.
Remarkably slow folding of a small protein
FEBS Lett.
(1997) - et al.
Effect of chemical glycosylation of RNase A on the protein stability and surface histidines accessibility in immobilized metal ion affinity electrophoresis (IMAGE) system
Biochim. Biophy. Acta
(1997) - et al.
Influence of glycerol on the structure and stability of ferric horse heart myoglobin: a SAXS and circular dichroism study
Biochim. Biophys. Acta.
(1996) - et al.
Physical stabilization of insulin by glycosylation
J. Pharm. Sci.
(1995) - et al.
Toward understanding insulin fibrillation
J. Pharm. Sci.
(1997) - et al.
The adsorption of proteins to pharmaceutical container surfaces
Int. J. Pharm.
(1992)